Clearing the Haze: What Employers Should Expect as Proposed Loosening of Federal Marijuana Regulation Moves Forward (US)

Why It Matters

The pending rescheduling reshapes federal drug policy, creating new compliance challenges and potential liability for employers nationwide.

Key Takeaways

• Trump order pushes DOJ to reschedule marijuana to Schedule III.
• Until rescheduling, federal drug testing rules remain unchanged.
• Employers can still ban workplace impairment post‑rescheduling.
• ADA accommodation claims may increase after Schedule III classification.
• State laws may still protect medical marijuana cardholders.

Pulse Analysis

The Trump administration’s December 2025 executive order marks a rare federal initiative to reevaluate marijuana’s scheduling. Moving the plant from Schedule I—reserved for substances with no accepted medical use—to Schedule III would align it with drugs like anabolic steroids, signaling broader acceptance of therapeutic applications. While the Department of Justice has been tasked with expediting rulemaking, the process historically spans months or years, leaving employers in a regulatory limbo where existing federal prohibitions still apply. This uncertainty compels HR leaders to monitor both the rulemaking timeline and emerging guidance from agencies such as the Department of Transportation, which continues to enforce strict testing for safety‑sensitive roles.

For businesses, the practical implications are twofold. First, current drug‑testing programs must remain in force for positions covered by DOT regulations, federal contracts, or internal safety policies, regardless of any future schedule change. Second, even after a potential reclassification, employers are expected to retain the ability to enforce impairment‑free workplaces, meaning pre‑employment screening and on‑the‑job testing can persist where justified by safety or productivity concerns. Moreover, the legal landscape around the Americans with Disabilities Act may evolve; a Schedule III designation could embolden employees to claim reasonable accommodations for medically prescribed marijuana, prompting employers to develop nuanced accommodation frameworks that balance disability rights with operational safety.

State and local jurisdictions add another layer of complexity. Numerous states already protect medical marijuana users from employment discrimination, and some limit the scope of drug testing. Companies operating across multiple jurisdictions must therefore harmonize federal compliance with a patchwork of state statutes, often requiring tailored policies for each location. Proactive steps include conducting a comprehensive policy audit, training managers on the distinction between use and impairment, and establishing clear documentation procedures for accommodation requests. By staying ahead of both federal rulemaking and state law developments, employers can mitigate litigation risk while fostering a workplace that respects evolving societal attitudes toward cannabis.